Increased sales of core brands including Advil, Caltrate and Robitussin drove up consumer sales 8% to $817 million for Pfizer’s fourth quarter. CEO Ian Read sees the segment “fitting nicely” in Pfizer following its animal health and nutrition business divestments.
Sales in Pfizer Inc.’s consumer and nutrition units grew despite lower companywide sales in the pharma firm’s latest quarter.
Increased sales of core brands including Advil, Caltrate and Robitussin drove up consumer sales 8% to $817 million for Pfizer’s...